Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate.
暂无分享,去创建一个
T. Ahmed | R. Nathan | K. Nolop | J. E. Harrison | F. Picone | J. Wolfe | A. Nayak | M. Lawrence | D. Graft | M. L. Vanderwalker | Mark L. Vanderwalker | J. Harrison
[1] M. Affrime,et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. , 2000, Chest.
[2] K. Nolop,et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[3] S. Peters,et al. Airway remodeling and persistent airway obstruction in asthma. , 1999, The Journal of allergy and clinical immunology.
[4] G. Settipane,et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. , 1999, Respiratory medicine.
[5] W. Kreutner,et al. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. , 1998, Arzneimittel-Forschung.
[6] R. Townley,et al. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] B. Lipworth,et al. Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. , 1997, American journal of respiratory and critical care medicine.
[8] M. Billah,et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. , 1997, The Journal of allergy and clinical immunology.
[9] P. O'Byrne,et al. A comparison of the efficacy and safety of inhaled corticosteroids in asthma , 1997, Allergy.
[10] K. Nolop,et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. , 1996, The Journal of allergy and clinical immunology.
[11] William H. Yang,et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] K. Nolop,et al. Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study , 1996, Allergy.
[13] N. Hanania,et al. Adverse effects of inhaled corticosteroids. , 1995, The American journal of medicine.
[14] S. Pedersen,et al. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. , 1994, Respiratory medicine.
[15] Alfred O. Berg,et al. Clinical Guidelines And Primary Care Guidelines For The Diagnosis And Management Of Asthma , 2012 .
[16] T. Haahtela,et al. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. , 1992, The Journal of allergy and clinical immunology.
[17] J. Kelly,et al. SAFETY AND EFFICACY OF MOMETASONE FUROATE CREAM IN THE TREATMENT OF STEROID RESPONSIVE DERMATOSES , 1991, The Australasian journal of dermatology.
[18] D. Cutler,et al. 62 Lack of systemic activity with intranasal mometasone furoate , 1996 .
[19] B. Barton,et al. Cytokine inhibition by a novel steroid, mometasone furoate. , 1991, Immunopharmacology and immunotoxicology.